

PreveCeutical Medical Inc.

10:16 14 Jan 2020

PreveCeutical beefs up type 2 diabetes-targeting Dual Gene Therapy program with new siRNA construct

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) has moved one step closer to completing its Dual Gene Therapy Program and the successful identification of its target gene-related to type 2 diabetes and obesity.

The Vancouver-based company announced Tuesday the addition of a potent small interfering RNA (siRNA) construct — which can be used to downregulate a specific targeted gene — to its roster.

The construct has been engineered into what the company calls its Smart-siRNA form and will soon be screened to evaluate its gene silencing capability. If successful, this would bring one aspect of PreveCeutical's Dual Gene Therapy Program to a close.

READ: PreveCeutical Medical sees positive results from safety appraisal of Sol-Gel formulations in nasal tissue

The design of the Smart-siRNA constructs is done with the final phase of the program in mind, in which the constructs' biostability will be crucial in assessing preclinical mice models of type 2 diabetes and obesity treatment.

"According to two of the pharmaceutical industry's top analysts, Paul Verdin and Lisa Urquhart of Evaluate Ltd, cell and gene therapy is at one of its most exciting phases of growth and has gained momentum with recent deal making, product sales and interest in the BioPharma sector," President Mak Jawadekar said in a statement. "With the progress that PreveCeutical has made with its Dual Gene Therapy Program, I believe that PreveCeutical could attract offers from companies in the BioPharma sector for future collaborations and partnerships."

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which

Price: 0.02

Market Cap: \$7.93 m

1 Year Share Price Graph



April 2019 September 2019 March 2020

Share Information

Code: PREV

Listing: CSE

52 week High Low
0.075 0.01

Sector: Medical technology & services

Website: preveceutical.com

Company Synopsis:

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

action@proactiveinvestors.com

any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to
Twenty Five Thousand dollars (\$25,000).